Department of General Surgery, Affiliated Hospital of Jiujiang University Jiangxi, China
Department of Pathology, Affiliated Hospital of Jiujiang University, Jiangxi, China
Balkan Med J. 2020 Jun 1;37(4):196-202. doi: 10.4274/balkanmedj.galenos.2020.2019.9.31. Epub 2020 Apr 9.
Donor organs for liver transplantation may often have fatty liver disease, which confers a higher sensitivity to ischemia/reperfusion injury. At present, there is no effective treatment for the condition. Evidence has suggested that metformin, the first-line medication for diabetes, has protective effects against many disorders. However, the potential role of metformin in ischemia/reperfusion injury in fatty liver disease remains unclear.
To examine the effect of metformin treatment during ischemia/reperfusion injury in fatty liver and determine the possible mechanisms.
Animal experimentation.
Sprague-Dawley male rats were fed a high-fat diet (520 kcal/100 g) for 14 weeks and then were subjected to the orthotopic autologous liver transplantation model. Sections of liver tissue were stained with hematoxylin and eosin to visualize the damage. Blood and liver samples were used to analyze the related proteins and components involved in the inflammatory signaling pathway.
We found that metformin significantly ameliorated the ischemia/reperfusion injury of the fatty liver through a reduction in alanine aminotransferase/aspartate aminotransferase concentrations in the serum and a decrease in dead cells, as shown by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay (p<0.05). In addition, metformin significantly attenuated interleukin (IL)-6, IL-1β, and tumor necrosis factor-α production and increased the expression of active caspase-3 and Bax in the liver (p<0.05). Mechanistically, metformin suppressed the activation of toll-like receptor 4 (TLR4)/NF-κB signaling (p<0.05), resulting in a decreased inflammatory response and apoptosis.
Our findings demonstrated that metformin attenuated ischemia/reperfusion injury in fatty liver disease via the TLR4/NF-κB axis, suggesting that metformin could have potential therapeutic applications in ischemia/reperfusion injury associated with liver transplantation.
用于肝移植的供体器官常常患有脂肪肝疾病,这使其对缺血/再灌注损伤更为敏感。目前,这种情况还没有有效的治疗方法。有证据表明,二甲双胍是治疗糖尿病的一线药物,对许多疾病都有保护作用。然而,二甲双胍在脂肪肝缺血/再灌注损伤中的潜在作用尚不清楚。
研究二甲双胍在脂肪肝缺血/再灌注损伤中的治疗作用,并确定可能的机制。
动物实验。
雄性 Sprague-Dawley 大鼠喂养高脂饮食(520 千卡/100 克)14 周,然后进行原位自体肝移植模型。肝组织切片用苏木精和伊红染色,以观察损伤情况。血液和肝脏样本用于分析炎症信号通路中涉及的相关蛋白和成分。
我们发现,二甲双胍通过降低血清中丙氨酸氨基转移酶/天冬氨酸氨基转移酶浓度和末端脱氧核苷酸转移酶介导的 dUTP 缺口末端标记法(TUNEL)检测到的死亡细胞数量减少,显著改善了脂肪肝的缺血/再灌注损伤(p<0.05)。此外,二甲双胍还显著降低了白细胞介素(IL)-6、IL-1β和肿瘤坏死因子-α的产生,并增加了肝脏中活性半胱天冬酶-3和 Bax 的表达(p<0.05)。机制上,二甲双胍抑制了 Toll 样受体 4(TLR4)/核因子-κB 信号通路的激活(p<0.05),从而减少了炎症反应和细胞凋亡。
我们的研究结果表明,二甲双胍通过 TLR4/NF-κB 轴减轻脂肪肝疾病的缺血/再灌注损伤,这表明二甲双胍在与肝移植相关的缺血/再灌注损伤中可能具有潜在的治疗应用。